Walter V. Klemp - Jun 20, 2025 Form 4 Insider Report for Moleculin Biotech, Inc. (MBRX)

Role
CEO and President, Director
Signature
/s/ Jonathan P. Foster by Power of Attorney
Stock symbol
MBRX
Transactions as of
Jun 20, 2025
Transactions value $
$249,171
Form type
4
Date filed
6/23/2025, 04:35 PM
Previous filing
Jun 18, 2025
Next filing
Aug 13, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
KLEMP WALTER V CEO and President, Director C/O MOLECULIN BIOTECH, INC., 5300 MEMORIAL DR., SUITE 950, HOUSTON /s/ Jonathan P. Foster by Power of Attorney 2025-06-23 0000938419

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MBRX Common Stock Options Exercise +3.75K +6.43% 62K Jun 20, 2025 Direct F1
transaction MBRX Common Stock Tax liability -$244 -914 -1.47% $0.27 61.1K Jun 20, 2025 Direct F2
transaction MBRX Common Stock Options Exercise +8.99K +14.71% 70.1K Jun 22, 2025 Direct F1
transaction MBRX Common Stock Tax liability -$585 -2.19K -3.12% $0.27 67.9K Jun 22, 2025 Direct F2
transaction MBRX Common Stock Purchase $250K +676K +994.63% $0.37 744K Jun 23, 2025 Direct F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MBRX Restricted Stock Units Options Exercise $0 -3.75K -0.95% $0.00 391K Jun 20, 2025 Common Stock 3.75K Direct F1, F3
transaction MBRX Restricted Stock Units Options Exercise $0 -8.99K -2.3% $0.00 382K Jun 22, 2025 Common Stock 8.99K Direct F1, F4
transaction MBRX Series E Warrants Purchase -2.03M -45.69% 2.41M Jun 23, 2025 Common Stock 2.03M $0.37 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units convert into common stock on a one-for-one basis.
F2 Shares withheld for payment of taxes upon vesting of restricted stock unit awards.
F3 On June 20, 2022, the reporting person was granted 15,000 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.
F4 On June 22, 2023, the reporting person was granted 35,959 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.
F5 On June 23, 2025, the reporting person acquired 675,675 shares of common stock and Series E warrants to purchase 2,027,025 shares of common stock at a purchase price of $0.37 per share and accompanying warrants in a public offering. The Series E warrants will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the Series E warrants and will expire five years from the date of such approval.